(CELG) |
|
0 (0%)
|
12-31 19:00 |
|
Open: |
|
Pre. Close: |
|
|
High:
|
|
Low:
|
|
|
Volume:
|
|
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2022-12-05 1:18:16 PM |
|
Overall:
|
 |
| Stoxline posted a STRONG SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 109.06  One year: 114.33 |
| Support: |
Support1: 86.08 Support2: 71.61 |
| Resistance: |
Resistance1: 93.37 Resistance2: 97.88 |
| Pivot: |
93.89 |
| Moving Average: |
MA(5): 93.54 MA(20): 93.21
MA(100): 82.58  MA(250): 0 |
| MACD: |
MACD(12,26): 0.9 Signal(9): 1.5 |
| Stochastic oscillator: |
%K(14,3): 39.9 %D(3): 58.2 |
| RSI: |
RSI(14): 45.9 |
| 52-week: |
High: 97.88 Low: 40.95 |
| Average Vol(K): |
3-Month: 2,167 (K) 10-Days: 1,450 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CEG ] has closed above bottom band by 11.2%. Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
93.67 - 94.2 |
94.2 - 94.78 |
|
Low:
|
89.55 - 90.14 |
90.14 - 90.78 |
|
Close:
|
90.93 - 91.95 |
91.95 - 93.07 |
|
Company Description |
|
|
Headline News |
Mon, 05 Dec 2022
Beta-thalassemia (B-thal) Market will generate new growth opportunities 2022-2028 | Celgene Corp., BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals - Digital Journal
Mon, 05 Dec 2022
Patent settlement and licence agreements - Lexology
Fri, 02 Dec 2022
Vaxxinity will push for approval of COVID booster after trial shows noninferiority to market leader Pfizer - FierceBiotech
Fri, 02 Dec 2022
Cellectar Biosciences announces former Celgene-BMS exec as new chief commercial officer - ROI-NJ.com
Fri, 02 Dec 2022
Philip Tagari switches Amgen's discovery lab for insitro's machine learning tools; CEO Joaquin Duato to chair J&J's board - Endpoints News
Wed, 30 Nov 2022
Endometrial Cancer Therapeutics Market 2021 Growth Drivers and Future Outlook | Top Brands Bristol-Myers Squibb Company, Merck KGaA, ArQule Inc., CELGENE, Janssen Pharmaceuticals, Pfizer, etc – Skegness Siren - Skegness Siren
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: |
| Sector: |
| Industry: |
| Shares Out. |
327 (M) |
| Shares Float |
327 (M) |
|
% Held by Insiders
|
0.2 (%) |
|
% Held by Institutions
|
83.3 (%) |
|
Shares Short
|
4,720 (K) |
|
Shares Short P.Month
|
4,120 (K) |
Stock Financials |
|
EPS
|
2.15 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
33.02 |
|
Profit Margin (%)
|
-0.7 |
|
Operating Margin (%)
|
0.1 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
-1.4 |
|
Qtrly Rev. Growth
|
37.2 |
|
Gross Profit (p.s.)
|
8.4 |
|
Sales Per Share
|
69.23 |
|
EBITDA (p.s.)
|
5.56 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-2,240 (M) |
|
Levered Free Cash Flow
|
151 (M) |
Stock Valuations |
|
PE Ratio
|
42.17 |
|
PEG Ratio
|
1.2 |
|
Price to Book value
|
2.74 |
|
Price to Sales
|
1.3 |
|
Price to Cash Flow
|
-13.24 |
Stock Dividends |
|
Dividend
|
0.14 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.1% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
